Here is the article I believe misiu143 may have been referencing which describes the two patients who experienced liver damage within 1-3 weeks of taking maraviroc.
Seems to be the reason at least a couple of other CCR5 antagonists were abandoned as well. This article mentions Aplaviroc
https://www.ncbi.nlm.nih.gov/books/NBK548266/
Seems to be the reason at least a couple of other CCR5 antagonists were abandoned as well. This article mentions Aplaviroc
https://www.ncbi.nlm.nih.gov/books/NBK548266/
Quote:Hepatotoxicity
Therapy with maraviroc was associated with alanine aminotransferase (ALT) elevations in up to 10% of patients, but elevations above 5 times normal are less common. Furthermore, rates of ALT elevations with maraviroc were similar to rates in comparator groups receiving similar background optimized antiretroviral therapy [2.6% vs 3.4% above 5 times ULN in one study and 3.9% vs 4.0% in a second]. These elevations have not been associated with clinical symptoms and generally did not require dose modification. Nevertheless, two cases of acute hepatocellular injury arose in patients receiving maraviroc in prelicensure clinical trials. Both were women, ages 24 and 27, who developed fever, fatigue and rash followed by liver tests abnormalities within 1 to 3 weeks of starting maraviroc. One patient remained anicteric (peak bilirubin 1.5 mg/dL) while the other developed marked jaundice (peak bilirubin 31 mg/dL) and underwent emergency liver transplantation 16 days after onset. In both instances, other potential causes were present but no other diagnosis was confirmed. For these reasons, hepatitis and hepatic failure are listed as adverse events in the product label which includes a boxed warning about hepatotoxicity. Aplaviroc, the initial CCR5 antagonist developed, was abandoned during preclinical testing because of concerns about hepatotoxicity. The clinical features of hepatotoxicity related to maraviroc have not been described in detail and the drug has had limited use. There have been no further reports of liver failure attributed to maraviroc therapy.
Likelihood score: D (possible rare cause of clinically apparent liver injury).
4
